

**Ref: STEX/Announcement/2024-25**

**Date: 26.04.2024**

**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street,**  
**Mumbai – 400001**

**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla complex**  
**Bandra(E) Mumbai- 400051**

**Code No: 531146**

**Symbol: MEDICAMEQ**

**Sub: Completion of US FDA Inspection at the Oncology Formulation facility of Medicamen Biotech Limited at Hardwar facility.**

**Dear Sir/ Ma'am,**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected the Oncology Formulation facility of Medicamen Biotech Limited located at Plot No. 84 & 85, Sector-6A, IIE, Sidcul, BHEL, Ranipur, Haridwar- 249403 from April 17, 2024 and concluded on today i.e. April 26, 2024 at 4:00 PM.

The inspection closed with 6 procedural observations which were complied with proactively and acknowledged by the auditor. However, the final approval (EIR) is expected after submission of formal response to FDA.

This is for your information and records.

**Thanking You**

**Yours truly,**  
**For Medicamen Biotech Limited**

**Parul Choudhary**  
**Company Secretary**  
**ACS: 44157**